Using engineered nanoparticles to slow Alzheimer's disease progression
Reduced Alzheimer's disease progression and neutrophil adhesion via competition using neutrophil-derived or engineered nanoparticles
This study is exploring a new way to help people with Alzheimer's by using tiny particles made from immune cells to improve blood flow in the brain and reduce inflammation, which could boost memory and thinking skills.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cornell University NIH-funded |
| Lab location | 1 site (Ithaca, United States) |
| Project ID | NIH-10799111 on NIH RePORTER |
What this research studies
This research investigates a new approach to treating Alzheimer's disease by using engineered nanoparticles derived from neutrophils. These nanoparticles aim to block the adhesion of neutrophils in the brain, which can cause reduced blood flow and contribute to cognitive decline. By improving blood circulation and reducing inflammation, the study seeks to enhance memory function in patients. The methodology involves advanced imaging techniques and the development of biocompatible agents that can be translated into clinical applications.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with Alzheimer's disease who experience cognitive decline and reduced blood flow in the brain.
Not a fit: Patients with other forms of dementia or those who do not have Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a novel treatment that slows the progression of Alzheimer's disease and improves cognitive function.
How similar studies have performed: While this approach is innovative, similar strategies targeting blood flow and inflammation in Alzheimer's have shown promise in preliminary studies, indicating potential for success.
Where this research is happening
Ithaca, United States
- Cornell University — Ithaca, United States (Active)
Researchers
- Principal investigator: Nishimura, Nozomi — Cornell University
- Study coordinator: Nishimura, Nozomi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.